1-4 of 4
Hengrui Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC

Hengrui Zhu, Jinhui Zhang, Han Yan, Xiao Ding, Juan Yang, Yu Jiang, Minjuan Deng, Haoxuan Song, Fangfang Ping, Fuyun Sun, Xiaoyu Li, Lijie Zhang, Bin Jiang, Weiwei Song, Zhirong Shen, Wei Jin, Jiyuan Zhang, Yun Zhang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4041.
https://doi.org/10.1158/1538-7445.AM2024-4041
Published: 22 March 2024
View article titled, Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and &lt; for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and &lt; for clinical potential in solid tumors such as HNSCC
Journal Articles

Abstract 1096: FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)

Douglas D. Fang, Hengrui Zhu, Qiuqiong Tang, Qixin Wang, Na Li, Xu Fang, Ping Min, Guangfeng Wang, Dajun Yang, Yifan Zhai
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1096.
https://doi.org/10.1158/1538-7445.AM2021-1096
Published: 01 July 2021
View article titled, Abstract 1096: FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)
Journal Articles

N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance

Takeshi Fukumoto, Hengrui Zhu, Timothy Nacarelli, Sergey Karakashev, Nail Fatkhutdinov, Shuai Wu, Pingyu Liu, Andrew V. Kossenkov, Louise C. Showe, Stephanie Jean, Lin Zhang, Rugang Zhang
Journal: Cancer Research
Cancer Res (2019) 79 (11): 2812–2820.
https://doi.org/10.1158/0008-5472.CAN-18-3592
Published: 03 June 2019
View article titled, N<sup>6</sup>-Methylation of Adenosine of <em>FZD10</em> mRNA Contributes to PARP Inhibitor Resistance
Open the PDF for N<sup>6</sup>-Methylation of Adenosine of <em>FZD10</em> mRNA Contributes to PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer

Yuhki Yokoyama, Hengrui Zhu, Jeong Heon Lee, Andrew V. Kossenkov, Sherry Y. Wu, Jayamanna M. Wickramasinghe, Xiangfan Yin, Katherine C. Palozola, Alessandro Gardini, Louise C. Showe, Kenneth S. Zaret, Qin Liu, David Speicher, Jose R. Conejo-Garcia, James E. Bradner, Zhiguo Zhang, Anil K. Sood, Tamas Ordog, Benjamin G. Bitler, Rugang Zhang
Journal: Cancer Research
Cancer Res (2016) 76 (21): 6320–6330.
https://doi.org/10.1158/0008-5472.CAN-16-0854
Published: 31 October 2016
View article titled, BET Inhibitors Suppress ALDH Activity by Targeting <em>ALDH1A1</em> Super-Enhancer in Ovarian Cancer
Open the PDF for BET Inhibitors Suppress ALDH Activity by Targeting <em>ALDH1A1</em> Super-Enhancer in Ovarian Cancer in another window
Includes: Supplementary data